河南太龙药业股份有限公司 关于控股股东筹划重大事项继续停牌的公告

Group 1 - The company is undergoing a significant matter involving the transfer of shares by its controlling shareholder, which may lead to a change in control [2][3] - The company's stock will be suspended from trading starting December 2, 2025, for a period not exceeding two trading days due to the uncertainty surrounding the share transfer [2] - The company has applied for an extension of the trading suspension until December 4, 2025, as discussions with the transaction parties are ongoing and internal approval processes are required [3] Group 2 - The company will continue to fulfill its information disclosure obligations during the suspension period, providing updates based on the progress of the matter [3] - Investors are advised to pay attention to subsequent announcements regarding the matter and to be aware of potential investment risks [4]